From PracticeUpdate website:
"TAKE-HOME MESSAGE
The authors report the management and outcomes of patients with elevated liver function test results secondary to abiraterone acetate therapy for metastatic prostate cancer. There were 46 liver disorder events seen in 25 men over 8 years at 3 French oncology centers. The median time from the start of treatment to the detection of liver toxicity was 7.1 weeks. In 52% of patients, liver function tests returned to baseline spontaneously while abiraterone was continued at full dose.
Liver events associated with abiraterone are rare and usually occur within the first 2 months of therapy. Most cases will resolve spontaneously."